益气抗癌活血方联合化疗治疗中晚期胃癌气虚血瘀证的效果及免疫功能分析  

Effect and Immune Function Analysis of Yiqi Kangai Huoxue Formula Combined with Chemotherapy on Qi Deficiency and Blood Stasis Syndrome of Advanced Gastric Cancer

作　　者：过杰 陈媛媛 黄逸姣 向培 GUO Jie;CHEN Yuanyuan;HUANG Yijiao;XIANG Pei(Department of Oncology,Wuxi Second Hospital of Traditional Chinese Medicine,Wuxi 214000,China)

机构地区：[1]无锡市第二中医医院肿瘤科,江苏无锡214000

出　　处：《中医药学报》2024年第8期84-88,共5页Acta Chinese Medicine and Pharmacology

基　　金：无锡市卫生健康委科研项目(ZYZL201809)。

摘　　要：目的:分析益气抗癌活血方联合化疗治疗中晚期胃癌气虚血瘀证的效果及对免疫功能的影响。方法:选取无锡市第二中医医院2019年2月—2021年7月就诊的中晚期胃癌气虚血瘀证患者106例,根据随机数字表法分为对照组及研究组,每组53例。对照组接受化疗治疗,研究组在对照组的基础上增加益气抗癌活血方治疗。3周为1个疗程。两组均治疗3个疗程。比较两组中医证候积分、临床疗效、胃肠激素、肿瘤标志物、免疫功能及不良反应。结果:治疗后,两组中医证候积分均降低(P<0.05),且研究组低于对照组(P<0.01)。研究组总有效率为67.92%(36/53),对照组总有效率为49.06%(26/53),研究组高于对照组(P<0.05)。治疗后,两组血清胃蛋白酶原Ⅰ(PGⅠ)、促胃液素(GAS)及胃蛋白酶原Ⅱ(PGⅡ)水平均升高(P<0.05),且研究组高于对照组(P<0.01)。治疗后,两组血清糖链抗原72-4(CA72-4)、癌胚抗原(CEA)、糖链抗原125(CA125)水平均降低(P<0.05),且研究组低于对照组(P<0.01)。治疗后,对照组CD3^(+)、CD4^(+)水平均降低(P<0.05),CD8^(+)水平升高(P<0.05),研究组CD3^(+)、CD4^(+)水平均升高(P<0.05),CD8^(+)水平降低(P<0.05),且研究组治疗后CD3^(+)、CD4^(+)水平高于对照组(P<0.01),CD8^(+)水平低于对照组(P<0.01)。两组肝肾毒性、神经毒性、骨髓抑制、胃肠道反应等不良反应发生率比较,差异无统计学意义(P>0.05)。结论:益气抗癌活血方联合化疗治疗中晚期胃癌气虚血瘀证疗效确切,可降低血清CA72-4、CEA、CA125水平,改善胃肠激素水平及免疫功能,且安全可靠。Objective:To analyze the effect of Yiqi Kangai Huoxue formula(YKHF)combined with chemotherapy on the syndrome of qi deficiency and blood stasis in advanced gastric cancer and its influence on immune function.Methods:A hundred and six patients with qi deficiency and blood stasis syndrome of mid to late stage gastric cancer admitted to Wuxi Second Hospital of Traditional Chinese Medicine from February 2019 to July 2021 were selected and divided into control group(n=53)and study group(n=53)according to random number table method.The control group was treated with chemotherapy,and the study group was treated the same in addition to YKHF.A treatment course lasts for three weeks,and both groups were treated for 3 courses.TCM syndrome scores,clinical efficacy,gastrointestinal hormones,tumor markers,immune function and adverse reactions were compared between the two groups.Results:After treatment,TCM syndrome scores in both groups decreased(P<0.05),which were lower in the study group than in control group(P<0.01).The total effective rate of the study group was 67.92%(36/53),and that of the control group was 49.06%(26/53)(P<0.05).After treatment,the serum levels of pepsinogenⅠ(PG-Ⅰ),gastrin(GAS)and pepsinogenⅡ(PG-Ⅱ)in 2 groups increased(P<0.05),and their serum levels in study group were higher than those in control group(P<0.01).After treatment,the serum levels of carbohydrate antigen 72-4(CA72-4),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in 2 groups decreased(P<0.05),and their serum levels in the study group were lower than those in the control group(P<0.01).After treatment,CD3^(+)and CD4^(+)levels in the control group decreased(P<0.05),and CD8^(+)levels increased(P<0.05);while CD3^(+)and CD4^(+)levels in the study group increased(P<0.05),while CD8^(+)levels in the study group decreased(P<0.05).The levels of CD3^(+)and CD4^(+)in the study group after treatment were higher than those of control group(P<0.01),while the levels of CD8^(+)in the study group after treatment were lower than those o

关 键 词：益气抗癌活血方 化疗 中晚期胃癌 气虚血瘀证 免疫功能 

分 类 号：R273[医药卫生—中西医结合]